3月18日,康哲药业(00867)发布截至2024年12月31日止年度业绩公告。报告期内,公司营业额下降6.8%至74.69亿元,去年同期为80.13亿元。若按药品销售收入计算,营业额下降9%至86.22亿元,主要因受到国家带量采购政策影响。毛利下降11.2%至54.22亿元,毛利率为72.6%,较去年同期的76.2%下降3.6个百分点。
年度溢利为16.13亿元,同比下降32.3%。正常化年度溢利下降36.7%至17.14亿元,主要因三款药品受到国家带量采购影响,营业额下降及费用支出增加。每股基本盈利为0.6673元,较去年同期下降31.9%。此外,年度总股息为每股0.2681元,同比下降31.6%。报告期内,银行结余及现金为37.07亿元,较去年同期减少。
在管理层讨论与分析中提到,公司新产品研发持续推进,报告期内新药获批上市及新增适应症的产品数量增加,显示出公司在创新药物开发方面的努力。尽管面临国家政策带来的挑战,公司依然通过优化产品结构和加大研发投入,推动业务的可持续发展。报告期内,皮肤医美业务表现良好,实现收入增长18.2%。总体来看,公司的业务分部中,皮肤医美和眼科业务增速较快,显示出良好的市场潜力。
(文章来源:财中社)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.